JP6106264B2 - 乳酸塩の定量のための遺伝学的にコードされたプローブならびに代謝速度および乳酸塩輸送の定量方法 - Google Patents
乳酸塩の定量のための遺伝学的にコードされたプローブならびに代謝速度および乳酸塩輸送の定量方法 Download PDFInfo
- Publication number
- JP6106264B2 JP6106264B2 JP2015505696A JP2015505696A JP6106264B2 JP 6106264 B2 JP6106264 B2 JP 6106264B2 JP 2015505696 A JP2015505696 A JP 2015505696A JP 2015505696 A JP2015505696 A JP 2015505696A JP 6106264 B2 JP6106264 B2 JP 6106264B2
- Authority
- JP
- Japan
- Prior art keywords
- lactate
- rate
- sequence number
- nanosensor
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 title claims description 294
- 238000000034 method Methods 0.000 title claims description 85
- 108010041817 Monocarboxylic Acid Transporters Proteins 0.000 title claims description 40
- 102000000562 Monocarboxylic Acid Transporters Human genes 0.000 title claims description 40
- 238000011002 quantification Methods 0.000 title description 12
- 239000000523 sample Substances 0.000 title description 12
- 230000037323 metabolic rate Effects 0.000 title description 8
- 210000004027 cell Anatomy 0.000 claims description 142
- 238000004519 manufacturing process Methods 0.000 claims description 56
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 49
- 230000003834 intracellular effect Effects 0.000 claims description 40
- 210000001519 tissue Anatomy 0.000 claims description 36
- 230000002438 mitochondrial effect Effects 0.000 claims description 34
- 238000004113 cell culture Methods 0.000 claims description 23
- 238000009825 accumulation Methods 0.000 claims description 18
- 108010082025 cyan fluorescent protein Proteins 0.000 claims description 18
- 238000001327 Förster resonance energy transfer Methods 0.000 claims description 16
- 108091006047 fluorescent proteins Proteins 0.000 claims description 14
- 102000034287 fluorescent proteins Human genes 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 210000003470 mitochondria Anatomy 0.000 claims description 13
- 108091005957 yellow fluorescent proteins Proteins 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 12
- 230000001464 adherent effect Effects 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- YMHOBZXQZVXHBM-UHFFFAOYSA-N 2,5-dimethoxy-4-bromophenethylamine Chemical compound COC1=CC(CCN)=C(OC)C=C1Br YMHOBZXQZVXHBM-UHFFFAOYSA-N 0.000 claims description 10
- 241000545067 Venus Species 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 8
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 8
- 239000005090 green fluorescent protein Substances 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 108091005948 blue fluorescent proteins Proteins 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000002452 interceptive effect Effects 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 229940126127 monocarboxylate transporter inhibitor Drugs 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 150000003893 lactate salts Chemical class 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 22
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 22
- 238000005259 measurement Methods 0.000 description 19
- 210000001130 astrocyte Anatomy 0.000 description 17
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 239000000370 acceptor Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 12
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 11
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000002123 temporal effect Effects 0.000 description 11
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 10
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 230000006682 Warburg effect Effects 0.000 description 8
- 108091008324 binding proteins Proteins 0.000 description 8
- 230000004907 flux Effects 0.000 description 8
- 230000010627 oxidative phosphorylation Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 108010078791 Carrier Proteins Proteins 0.000 description 7
- 208000032612 Glial tumor Diseases 0.000 description 7
- 206010018338 Glioma Diseases 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000002414 glycolytic effect Effects 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 102200082402 rs751610198 Human genes 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000006677 mitochondrial metabolism Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 241000186226 Corynebacterium glutamicum Species 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 108010092494 Periplasmic binding proteins Proteins 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 150000001540 azides Chemical class 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000295 emission spectrum Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000034659 glycolysis Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000013178 mathematical model Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000001506 fluorescence spectroscopy Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BBBSAMGPHQIMQG-UHFFFAOYSA-N 2-oxopropanoic acid;hydrochloride Chemical compound Cl.CC(=O)C(O)=O BBBSAMGPHQIMQG-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 230000004108 pentose phosphate pathway Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XFVULMDJZXYMSG-ZIYNGMLESA-N 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylic acid Chemical compound NC1=C(C(O)=O)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 XFVULMDJZXYMSG-ZIYNGMLESA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 108091005960 Citrine Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108050005244 Monocarboxylate transporters Proteins 0.000 description 1
- 102000017298 Monocarboxylate transporters Human genes 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 102000015982 Pannexin Human genes 0.000 description 1
- 108050004251 Pannexin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 239000011035 citrine Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000006539 extracellular acidification Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000006692 glycolytic flux Effects 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 230000037447 lactate metabolism Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000019261 negative regulation of glycolysis Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003702 neurovascular coupling effect Effects 0.000 description 1
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/033639 WO2013154587A1 (en) | 2012-04-13 | 2012-04-13 | Genetically encoded probe for quantification of lactate, and methods for quantifying metabolic rates and lactate transport |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512935A JP2015512935A (ja) | 2015-04-30 |
| JP2015512935A5 JP2015512935A5 (enExample) | 2016-05-12 |
| JP6106264B2 true JP6106264B2 (ja) | 2017-03-29 |
Family
ID=49327999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505696A Expired - Fee Related JP6106264B2 (ja) | 2012-04-13 | 2012-04-13 | 乳酸塩の定量のための遺伝学的にコードされたプローブならびに代謝速度および乳酸塩輸送の定量方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10466233B2 (enExample) |
| EP (1) | EP2836503B1 (enExample) |
| JP (1) | JP6106264B2 (enExample) |
| CA (1) | CA2870271C (enExample) |
| DK (1) | DK2836503T3 (enExample) |
| ES (1) | ES2602321T3 (enExample) |
| WO (1) | WO2013154587A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015025192A1 (en) * | 2013-08-20 | 2015-02-26 | Centro De Estudios Cientificos De Valdivia | Genetically encoded probe for quantification of pyruvate concentration and methods of using the same |
| DE102015115640B4 (de) * | 2015-09-16 | 2017-06-29 | Stiftung Caesar Center Of Advanced European Studies And Research | Verfahren zum Nachweis von Liganden vermittels Biosensoren |
| EP3377897B1 (en) * | 2015-11-20 | 2024-05-01 | Duke University | Lactate biosensors and uses thereof |
| EP3377904B1 (en) | 2015-11-20 | 2024-05-01 | Duke University | Urea biosensors and uses thereof |
| US20180371643A1 (en) * | 2015-11-30 | 2018-12-27 | Council Of Scientific & Industrial Research | Method of Identification of Combinatorial Enzymatic Reaction Targets in Glioblastoma Specific Metabolic Network |
| WO2018152480A1 (en) * | 2017-02-20 | 2018-08-23 | Richard Postrel | Method for precise identification, targeting and delivery of directed therapies for destruction of cancerous cells |
| US11175281B2 (en) | 2018-08-21 | 2021-11-16 | International Business Machines Corporation | Well plate cover with embedded electronic sensors for monitoring cell metabolism |
| KR102167605B1 (ko) * | 2019-05-20 | 2020-10-19 | 울산과학기술원 | 슈도모나스 플루오레센스 유래 신규 D-LldR 전사조절인자 기반의 D(-)-젖산 검출용 바이오 센서 |
| WO2021033015A1 (en) * | 2019-08-22 | 2021-02-25 | Centro De Estudios Científicos De Valdivia | Genetically encoded probe for detection and quantification of lactate/pyruvate ratio with high spatial and temporal resolution |
| CN113004420B (zh) * | 2019-12-19 | 2023-02-24 | 华东理工大学 | 乳酸光学探针及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3829252B2 (ja) * | 2001-06-08 | 2006-10-04 | 独立行政法人理化学研究所 | 蛍光蛋白質 |
| CA2457059A1 (en) | 2001-08-10 | 2003-02-20 | Ahram Biosystems Inc. | System for detecting protease |
| WO2003025220A2 (en) * | 2001-09-18 | 2003-03-27 | Carnegie Institution Of Washington | Fusion proteins useful for detecting analytes |
| AU2005295656B2 (en) * | 2004-10-14 | 2011-08-04 | Carnegie Institution Of Washington | Development of sensitive FRET sensors and methods of using the same |
| CA2599852A1 (en) * | 2005-03-04 | 2006-09-14 | Carnegie Institution Of Washington | Environmentally stable sensors and methods of using the same |
| US7790868B2 (en) * | 2005-05-20 | 2010-09-07 | The Governors Of The University Of Alberta | Teal fluorescent proteins (mTFP1) |
| US8173863B2 (en) * | 2005-10-14 | 2012-05-08 | Carnegie Institution Of Washington | Sucrose biosensors and methods of using the same |
-
2012
- 2012-04-13 CA CA2870271A patent/CA2870271C/en not_active Expired - Fee Related
- 2012-04-13 JP JP2015505696A patent/JP6106264B2/ja not_active Expired - Fee Related
- 2012-04-13 DK DK12874169.1T patent/DK2836503T3/en active
- 2012-04-13 US US14/394,018 patent/US10466233B2/en not_active Expired - Fee Related
- 2012-04-13 EP EP12874169.1A patent/EP2836503B1/en not_active Not-in-force
- 2012-04-13 WO PCT/US2012/033639 patent/WO2013154587A1/en not_active Ceased
- 2012-04-13 ES ES12874169.1T patent/ES2602321T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015512935A (ja) | 2015-04-30 |
| EP2836503A1 (en) | 2015-02-18 |
| WO2013154587A1 (en) | 2013-10-17 |
| EP2836503B1 (en) | 2016-06-08 |
| EP2836503A4 (en) | 2015-03-25 |
| DK2836503T3 (en) | 2016-09-19 |
| CA2870271C (en) | 2020-06-30 |
| ES2602321T3 (es) | 2017-02-20 |
| US20150072375A1 (en) | 2015-03-12 |
| US10466233B2 (en) | 2019-11-05 |
| CA2870271A1 (en) | 2013-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6106264B2 (ja) | 乳酸塩の定量のための遺伝学的にコードされたプローブならびに代謝速度および乳酸塩輸送の定量方法 | |
| San Martín et al. | A genetically encoded FRET lactate sensor and its use to detect the Warburg effect in single cancer cells | |
| Blay et al. | High-throughput screening: today’s biochemical and cell-based approaches | |
| Specht et al. | A critical and comparative review of fluorescent tools for live-cell imaging | |
| De Michele et al. | Mitochondrial biosensors | |
| Robida et al. | Bimolecular fluorescence complementation analysis of inducible protein interactions: effects of factors affecting protein folding on fluorescent protein fragment association | |
| Bermejo et al. | Optical sensors for measuring dynamic changes of cytosolic metabolite levels in yeast | |
| Sharma et al. | Peptide-based fluorescent sensors of protein kinase activity: design and applications | |
| Zhao et al. | Visualization of nicotine adenine dinucleotide redox homeostasis with genetically encoded fluorescent sensors | |
| Ahmad et al. | Live cell monitoring of glycine betaine by FRET-based genetically encoded nanosensor | |
| JP6257771B2 (ja) | ピルビン酸濃度の定量のための遺伝的にコードされたプローブ、およびその使用方法。 | |
| Manzoor et al. | Visualization of thiamine in living cells using genetically encoded fluorescent nanosensor | |
| Pelosse et al. | Genetically encoded fluorescent biosensors to explore AMPK signaling and energy metabolism | |
| Zhang et al. | Traditional and novel tools to probe the mitochondrial metabolism in health and disease | |
| Zhang et al. | A multifunctional fluorescent probe for tracking SO2 fluctuation between mitochondria and endoplasmic reticulum in living cells and zebrafish | |
| Yang et al. | Collaborative light-off and light-on bacterial luciferase biosensors: Innovative approach for rapid contaminant detection | |
| Lajoie et al. | Approaches to imaging unfolded secretory protein stress in living cells | |
| Kim et al. | Action of the chaperonin GroEL/ES on a non-native substrate observed with single-molecule FRET | |
| Haruyama | Cellular biosensing: chemical and genetic approaches | |
| JP2010520759A (ja) | 「順モード（ｆｏｒｗａｒｄｍｏｄｅ）」調節化合物において、ナトリウム−カルシウム交換体（ＮＣＸ）を調節する化合物を検出ための蛍光ベースのアッセイ | |
| CA2950051C (en) | Fluorescent amp-kinase biosensors | |
| WO2021033015A1 (en) | Genetically encoded probe for detection and quantification of lactate/pyruvate ratio with high spatial and temporal resolution | |
| US20220169682A1 (en) | Split photoactive yellow protein complementation system and uses thereof | |
| Lay et al. | Development of a BRET based chloride biosensor for high throughput screening of KCC2 modulators | |
| Chen et al. | Application of large-scale transient transfection to cell-based functional assays for ion channels and GPCRs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151215 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160719 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161018 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170221 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170303 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6106264 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |